Figure 6:

From left to right, transaxial ¹⁸F-FTT PET image, unenhanced CT scan, fused image, and contrast material–enhanced MR image in a 62-year-old woman with metastatic biphenotypic hepatocellular carcinoma/cholangiocarcinoma (subject 8, Table 2). The subject had previously undergone right hepatic trisegmentectomy and treatment with multiple chemotherapy regimens. The most recent chemotherapy regimen is described in Table 2. MR imaging was performed 1 month before ¹⁸F-FTT PET/CT and demonstrated new metastatic liver lesions with decreased signal intensity, as seen on MR image (arrow), in addition to enlargement of left hepatic lobe as a result of previous partial hepatic resection. CT (liver window) showed interval enlargement of metastasis, as demonstrated by low-attenuation lesion that is clearly larger than low-signal-intensity lesion seen on corresponding MR image. ¹⁸F-FTT image shows increased uptake within this metastasis. PET/CT images were obtained 150 minutes after tracer injection. MR image was obtained 20 minutes after gadoxetate disodium injection. Arrows show locations of metastatic lesions. Gray-scale PET images were set to same scale as that shown for color image. SUV = standardized uptake value.